

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
*Petitioner*

v.

CORCEPT THERAPEUTICS, INC.,  
*Patent Owner*

---

Case PGR2019-00048  
U.S. Patent No. 10,195,214

---

**DECLARATION OF DANIEL C. WIESNER IN SUPPORT OF  
PATENT OWNER'S MOTION FOR  
*PRO HAC VICE* ADMISSION UNDER 37 C.F.R. § 42.10(c)**

I, Daniel C. Wiesner, declare as follows:

1. I am Of Counsel at the law firm Quinn Emanuel Urquhart & Sullivan, LLP.

I am a member in good standing of the State Bar of New York, and have practiced patent litigation since 2004.

2. I have never been suspended or disbarred from practice before any court or administrative body.

3. I have never had any application for admission to practice before any court or administrative body denied.

4. I have never been the subject of any sanctions or contempt citations imposed by any court or administrative body.

5. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of the C.F.R.

6. I will be subject to the USPTO Code of Professional Responsibility and disciplinary jurisdiction.

7. I have previously applied to appear *pro hac vice* before the Patent and Trademark Office in *Actavis LLC v. Abraxis Bioscience, LLC*, IPR2017-01101, IPR2017-01103, IPR2017-01104 (PTAB), and was admitted.

8. I have an established familiarity with the subject matter at issue in this Post Grant Review. Specifically, I have experience representing Corcept Therapeutics, Inc. ("Corcept") with respect to the subject matter at issue in this Post Grant

Review, including the specific patent and prior art at issue. In addition, I am trial counsel for Corcept in the patent litigation against Teva concerning the patent challenged in the petition (*Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et. al*, No. 2:18-cv-03632-SDW-CLW (D.N.J.)).

I declare under penalty of perjury that the foregoing is true and correct.

Date: June 16, 2020

/Daniel C. Wiesner/

---

Daniel C. Wiesner